CD274 and cancer: Cancer immunotherapy, particularly with PD‐1/PD‐L1 antibodies, has demonstrated remarkable clinical success in treating solid tumors recently, marking a groundbreaking advancement in oncology, offering renewed hope and a potential turning point for patients battling cancer [41, 42, 43].